ePT--the Electronic Newsletter of Pharmaceutical Technology, Nov 23, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Nov 23, 2011
News
House Bill Would Stiffen Penalties for Drug Counterfeiters
By Amy Ritter
On Nov. 17, 2011, a bill that would increase penalties for those convicted of trafficking in counterfeit drugs was introduced in the House of Representatives. The Counterfeit Drug Penalty Enhancement Act of 2011, cosponsored by four US Senators and two US Representatives.
Ben Venue Suspends Manufacturing at Bedford Plant
By Erik Greb
On Nov. 19, 2011, Ben Venue Laboratories voluntarily and temporarily suspended the manufacture and distribution of products made at its Bedford, Ohio, facility. These products include Doxil (doxorubicin HCl liposome injection), which the company produces for Johnson & Johnson. The company's clients include Pfizer, Hospira, and Teva.
SOCMA Raises Concern Over Proposed Legislation for TSCA Reform
By Patricia Van Arnum
The Society of Chemical Manufacturers and Affiliates issued a statement to the US Senate Committee on Environment and Public Works supporting the evaluation of national chemical-control laws but specifically opposing the Safe Chemicals Act, which was introduced earlier this year by Sen. Frank Lautenberg (D-NJ).
European Action Against Antimicrobial Resistance
By Stephanie Sutton
The European Commission has unveiled a comprehensive action plan against antimicrobial resistance that includes provisions to promote R&D as well as the possibility of establishing fast-track procedures for marketing authorizations.
Week of Nov. 21, 2011: Pfizer, MIT Break Ground on New Research Units in Massachusetts; PhRMA Names Richard I. Smith Executive Vice-President of Policy and Research; and More
Pfizer, MIT Break Ground on New Research Units in Massachusetts; PhRMA Names Richard I. Smith Executive Vice-President of Policy and Research; and More.
Regulatory Roundup: FDA Holds Special Press Briefing Regarding Revocation of Genentech's Avastin
FDA Holds Special Press Briefing Regarding Revocation of Genentech's Avastin.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
21%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
8%
Regulatory compliance
42%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Click here